Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$24.02 -1.9%	$22.00	$14.40 ▼ $47.00	$1.60B	1.22	956,908 shs	1.36 million shs
DVAX Dynavax Technologies	$10.49 -2.5%	$10.58	$9.22 ▼ $14.63	$1.23B	1.09	2.07 million shs	940,228 shs
LXRX Lexicon Pharmaceuticals	$1.16 -4.1%	$1.01	$0.28 ▼ $2.18	$421.54M	1.17	8.69 million shs	1.79 million shs
NVAX Novavax	$9.52 -2.0%	$7.19	$5.01 ▼ $15.22	$1.55B	2.5	6.65 million shs	4.39 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	-4.00%	+22.34%	+9.24%	+19.47%	-28.38%
DVAX Dynavax Technologies	-0.28%	+2.67%	+0.37%	+3.26%	-3.93%
LXRX Lexicon Pharmaceuticals	-2.42%	+16.35%	-1.63%	+112.28%	-27.11%
NVAX Novavax	+1.36%	+20.85%	+38.71%	+26.43%	-25.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	1.5858 of 5 stars	3.4	3.0	0.0	1.4	0.0	0.0
DVAX Dynavax Technologies	4.4075 of 5 stars	3.3	2.0	4.7	2.7	1.7	1.9
LXRX Lexicon Pharmaceuticals	2.6625 of 5 stars	3.3	3.0	0.0	2.1	2.5	0.6
NVAX Novavax	4.6267 of 5 stars	3.1	2.0	4.7	3.3	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.89	Moderate Buy	$51.75	115.45% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.33	131.97% Upside
LXRX Lexicon Pharmaceuticals	2.50	Moderate Buy	$3.23	178.02% Upside
NVAX Novavax	2.25	Hold	$15.86	66.57% Upside

Current Analyst Ratings Breakdown

Latest LXRX, CLDX, NVAX, and DVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$31.00 ➝ $32.00
8/7/2025	LXRX Lexicon Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1.20 ➝ $1.90
7/22/2025	NVAX Novavax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
6/24/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.02M	227.23	N/A	N/A	$11.26 per share	2.13
DVAX Dynavax Technologies	$277.25M	4.44	$0.15 per share	68.14	$4.54 per share	2.31
LXRX Lexicon Pharmaceuticals	$31.08M	13.56	N/A	N/A	$0.40 per share	2.90
NVAX Novavax	$682.16M	2.27	N/A	N/A	($3.89) per share	-2.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$157.86M	-$3.01	N/A	N/A	N/A	-3,446.88%	-27.61%	-26.20%	11/5/2025 (Estimated)
DVAX Dynavax Technologies	$27.31M	-$0.46	N/A	21.41	N/A	-16.67%	5.10%	3.00%	11/6/2025 (Estimated)
LXRX Lexicon Pharmaceuticals	-$200.40M	-$0.33	N/A	N/A	N/A	-206.43%	-83.63%	-42.22%	N/A
NVAX Novavax	-$187.50M	$2.28	4.18	119.00	0.11	39.20%	-142.33%	28.65%	N/A

Latest LXRX, CLDX, NVAX, and DVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CLDX Celldex Therapeutics	-$0.86	-$0.85	+$0.01	-$0.85	$1.13 million	$0.73 million
8/7/2025	Q2 2025	DVAX Dynavax Technologies	$0.12	$0.14	+$0.02	$0.14	$87.55 million	$95.44 million
8/6/2025	Q2 2025	LXRX Lexicon Pharmaceuticals	-$0.08	$0.01	+$0.09	$0.01	$4.87 million	$28.87 million
8/6/2025	Q2 2025	NVAX Novavax	-$0.07	$0.62	+$0.69	$0.62	$149.19 million	$239.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	19.67	19.67
DVAX Dynavax Technologies	0.45	6.65	6.01
LXRX Lexicon Pharmaceuticals	0.43	4.16	4.16
NVAX Novavax	5.93	2.36	2.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
DVAX Dynavax Technologies	96.96%
LXRX Lexicon Pharmaceuticals	74.70%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	4.40%
DVAX Dynavax Technologies	2.98%
LXRX Lexicon Pharmaceuticals	13.90%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.41 million	63.49 million	Optionable
DVAX Dynavax Technologies	350	117.27 million	113.77 million	Optionable
LXRX Lexicon Pharmaceuticals	140	363.40 million	312.89 million	Optionable
NVAX Novavax	1,990	162.42 million	160.80 million	Optionable

LXRX, CLDX, NVAX, and DVAX Headlines

Recent News About These Companies

Entropy Technologies LP Invests $191,000 in Novavax, Inc. (NASDAQ:NVAX)

August 18 at 4:21 AM | marketbeat.com

Novavax (NASDAQ:NVAX) Trading 5.4% Higher - Here's What Happened

August 16 at 2:30 PM | marketbeat.com

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

August 13, 2025 | zacks.com

Novavax (NASDAQ:NVAX) Trading Down 5.7% - Here's Why

August 12, 2025 | marketbeat.com

B. Riley Comments on Novavax's FY2027 Earnings (NASDAQ:NVAX)

August 12, 2025 | marketbeat.com

XTX Topco Ltd Buys Shares of 67,803 Novavax, Inc. (NASDAQ:NVAX)

August 10, 2025 | marketbeat.com

Novavax Stock Surges Amid Strategic Gains

August 10, 2025 | msn.com

FDA reinstates top vaccines regulator just days after his abrupt departure

August 9, 2025 | msn.com

Brokerages Set Novavax, Inc. (NASDAQ:NVAX) PT at $15.86

August 9, 2025 | americanbankingnews.com

TD Cowen Reaffirms Their Hold Rating on Novavax (NVAX)

August 8, 2025 | theglobeandmail.com

Novavax (NASDAQ:NVAX) Stock Price Up 14.6% After Better-Than-Expected Earnings

August 8, 2025 | marketbeat.com

Novavax (NASDAQ:NVAX) Trading 14.6% Higher Following Strong Earnings

August 8, 2025 | americanbankingnews.com

Novavax (NASDAQ:NVAX) Shares Gap Up on Earnings Beat

August 8, 2025 | americanbankingnews.com

NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View

August 7, 2025 | zacks.com

Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Call Transcript

August 7, 2025 | msn.com

Novavax (NASDAQ:NVAX) Shares Gap Up Following Earnings Beat

August 7, 2025 | marketbeat.com

Novavax lifts 2025 revenue outlook after FDA milestone payment

August 7, 2025 | finance.yahoo.com

Novavax banks on vaccine supply partnerships to boost 2025 revenue

August 7, 2025 | msn.com

Novavax higher after Q2 beat as partnerships brighten outlook

August 7, 2025 | msn.com

Decoding Novavax Inc (NVAX): A Strategic SWOT Insight

August 6, 2025 | gurufocus.com

Q2 2025 Novavax Inc Earnings Call Transcript

August 6, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX, CLDX, NVAX, and DVAX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$24.02 -0.46 (-1.88%)

Closing price 04:00 PM Eastern

Extended Trading

$20.63 -3.39 (-14.13%)

As of 07:06 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Dynavax Technologies NASDAQ:DVAX

$10.49 -0.27 (-2.51%)

Closing price 04:00 PM Eastern

Extended Trading

$10.45 -0.04 (-0.38%)

As of 06:09 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.16 -0.05 (-4.13%)

Closing price 04:00 PM Eastern

Extended Trading

$1.16 0.00 (-0.43%)

As of 06:44 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Novavax NASDAQ:NVAX

$9.52 -0.19 (-1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$9.51 -0.01 (-0.16%)

As of 07:12 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time